Roche spins out Nimble Therapeutics to capitalize on peptide drug discovery, with $10M support from Telegraph Hill Partners

In 2007, Roche Diagnostics acquired Madison, Wisconsin-based NimbleGen as it looked to add DNA microarray tech to its genomics research toolkit. The pharma giant has since shuttered the unit, laid off staffers and announced it would close the site altogether, but the technology is living on as a drug discovery platform in a new spinout.